Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

NCT03984812 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
24
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early (following completion of SAD Cohort 3; 80 mg) based on PK/PD modelling which demonstrated the medicine's intended target profile was not achievable.

Conditions

Interventions

Sponsor

ViiV Healthcare